Search - tctmd.com

Displaying 201 - 220 of 222

Sort: Relevancy | Date

Dapagliflozin Has Benefits Across Heart Failure Subgroups

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

November 17, 2019

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

October 21, 2019

Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF

News Conference News HFSA 2019

Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF

September 23, 2019

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

News Conference News HFSA 2019

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

September 18, 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

News Conference News HFSA 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

September 16, 2019

Primary Prevention ICDs Still Render Better Survival, Even in Modern HFrEF Patients

News Conference News ESC 2019

Primary Prevention ICDs Still Render Better Survival, Even in Modern HFrEF Patients

September 13, 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

News Conference News ESC 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Yael L. Maxwell

September 12, 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

September 01, 2019

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

News Daily News

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

August 20, 2019

Rivaroxaban Cuts Major Stroke Risk in COMMANDER HF Post Hoc Analysis

News Conference News ESC Heart Failure 2019

Rivaroxaban Cuts Major Stroke Risk in COMMANDER HF Post Hoc Analysis

May 26, 2019

BeAT-HF: Baroreflex Activation Therapy Improves Outcomes in Subset of HF Patients

News Conference News HRS 2019

BeAT-HF: Baroreflex Activation Therapy Improves Outcomes in Subset of HF Patients

May 15, 2019

Digging In: Adherence to Plant-Based Diets Linked to Fewer HF Hospitalizations

News Daily News

Digging In: Adherence to Plant-Based Diets Linked to Fewer HF Hospitalizations

April 23, 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

March 26, 2019

FDA Approves the Optimizer Smart Implantable Pulse Generator for Heart Failure

News Daily News

FDA Approves the Optimizer Smart Implantable Pulse Generator for Heart Failure

Yael L. Maxwell

March 22, 2019

How HF Drugs Help and Harm Female Patients: A Call for Sex-Specific Reporting

News Daily News

How HF Drugs Help and Harm Female Patients: A Call for Sex-Specific Reporting

February 26, 2019

News Industry News

Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure

February 25, 2019

Novel Interatrial Shunt Shows Promise at 1 Year in HF Patients With Reduced and Preserved EF

News Daily News

Novel Interatrial Shunt Shows Promise at 1 Year in HF Patients With Reduced and Preserved EF

November 02, 2018

Novel Interatrial Shunt Succeeds in HF Hemodynamic Study

News Conference News AHA 2017

Novel Interatrial Shunt Succeeds in HF Hemodynamic Study: REDUCE LAP-HF I

Michael O'Riordan

November 21, 2017

News Industry News

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

August 31, 2015

News Industry News

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

July 07, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.